Zeev Blumenfeld1, Biren Patel, Ronit Leiba, Tsila Zuckerman. 1. Reproductive Endocrinology and Bone Marrow Transplantation Units, RAMBAM Health Care Campus, Rappaport Institute and Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel. bzeev@techunix.technion.ac.il
Abstract
OBJECTIVE: To compare the rate of premature ovarian failure (POF) after stem cell transplantation (SCT) in young women receiving GnRH-agonist (GnRH-a) in conjunction with gonadotoxic chemotherapy. DESIGN: Prospective, nonrandomized study. SETTING: Tertiary university hospital. PATIENT(S): Ninety-five women received conditioning chemotherapy, with or without GnRH-a before SCT. Complete information was available for only 83 patients. INTERVENTION(S): Conditioning chemotherapy, with or without GnRH-a before SCT. MAIN OUTCOME MEASURE(S): Cyclic ovarian function (COF) or POF after SCT. RESULT(S): There were no significant differences in age, chemotherapy treatment, or diagnoses between the study and control groups. In the GnRH-a group, 38.3% (18/47) patients resumed COF, compared with 11.1% (4/36) for patients who did not receive GnRH-a. Patients who resumed COF were on average 3.7 years (median, 3 years) younger at the time of transplantation than those who experienced POF. GnRH-a had a significant effect on long-term COF in patients with lymphomas (66.7% [14/21] for GnRH-a group vs. 18.2% [2/11] for control) but not for leukemia patients. CONCLUSION(S): GnRH-a cotreatment in conjunction with conditioning chemotherapy before SCT may significantly decrease the gonadotoxicity and POF from 82% to 33% in lymphoma but not in leukemia patients.
OBJECTIVE: To compare the rate of premature ovarian failure (POF) after stem cell transplantation (SCT) in young women receiving GnRH-agonist (GnRH-a) in conjunction with gonadotoxic chemotherapy. DESIGN: Prospective, nonrandomized study. SETTING: Tertiary university hospital. PATIENT(S): Ninety-five women received conditioning chemotherapy, with or without GnRH-a before SCT. Complete information was available for only 83 patients. INTERVENTION(S): Conditioning chemotherapy, with or without GnRH-a before SCT. MAIN OUTCOME MEASURE(S): Cyclic ovarian function (COF) or POF after SCT. RESULT(S): There were no significant differences in age, chemotherapy treatment, or diagnoses between the study and control groups. In the GnRH-a group, 38.3% (18/47) patients resumed COF, compared with 11.1% (4/36) for patients who did not receive GnRH-a. Patients who resumed COF were on average 3.7 years (median, 3 years) younger at the time of transplantation than those who experienced POF. GnRH-a had a significant effect on long-term COF in patients with lymphomas (66.7% [14/21] for GnRH-a group vs. 18.2% [2/11] for control) but not for leukemiapatients. CONCLUSION(S): GnRH-a cotreatment in conjunction with conditioning chemotherapy before SCT may significantly decrease the gonadotoxicity and POF from 82% to 33% in lymphoma but not in leukemiapatients.
Authors: R Phelan; E Mann; C Napurski; T E DeFor; A Petryk; W P Miller; J E Wagner; M R Verneris; A R Smith Journal: Bone Marrow Transplant Date: 2016-06-06 Impact factor: 5.483
Authors: Alexandra Higgins; Zaraq Khan; Charles C Coddington; Shahrukh K Hashmi; Mehrdad Hefazi; Hassan Alkhateeb; Mark R Litzow; William J Hogan; Elizabeth Cathcart-Rake; Carrie A Thompson; Mrinal M Patnaik Journal: Biol Blood Marrow Transplant Date: 2019-02-15 Impact factor: 5.742